Innofactor Plc
Innofactor Plc Annual Report for 2024 has been published
Innofactor Plc Annual Report for 2024 has been published
Innofactor Plc Annual Financial Report, on March 31, 2025, at 9:00 Finnish time
Innofactor Annual Report for 2024 has been published as a PDF file on the company website: www.innofactor.com/invest-in-us/releases-publications-and-reports/#annual-reports. The Annual Report includes the Financial Statement, the Report of the Board of Directors and the Sustainability Report.
Innofactor's Corporate Governance Statement for the Financial Period 2024 has been published separately from the Annual Report on the company website: https://www.innofactor.com/invest-in-us/corporate-governance/.
The Remuneration Report for the Financial Period 2024 has been published on the company website: www.innofactor.com/invest-in-us/corporate-governance/#compensations.
The Annual Report, the Corporate Governance Statement, and the Remuneration Report are also attached to this release.
Espoo, March 31, 2025
INNOFACTOR PLC
Sami Ensio, CEO
Additional information:
Sami Ensio, CEO
Innofactor Plc
Tel. +358 50 584 2029
sami.ensio@innofactor.com
Distribution:
NASDAQ Helsinki
Main media
www.innofactor.com
Innofactor
Innofactor is the leading driver of the modern digital organization in the Nordic Countries for its about 1,000 customers in commercial and public sector. Innofactor has the widest solution offering and leading know-how in the Microsoft ecosystem in the Nordics. Innofactor has about 600 enthusiastic and motivated top specialists in Finland, Sweden, Denmark and Norway. www.innofactor.com #AIDriven #PeopleFirst #BeTheRealYou
Attachments
- Innofactor Plc Annual Report 2024
- Corporate Governance Statement 2024
- Remuneration Report 2024
Attachments
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novartis Pharma AG3.4.2025 02:13:00 CEST | Press release
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
CRUSHON AI CORP3.4.2025 02:05:57 CEST | Press release
Crushon AI Adds Target Play for Spicy AI and NSFW Character Chats
Appian Capital Advisory2.4.2025 22:34:00 CEST | Press release
Appian completes sale of MVV to Baiyin Nonferrous for US$420 million
Nokia Oyj2.4.2025 21:45:00 CEST | Press release
Nokia completes the share buyback program launched in November 2024
Nokia Oyj2.4.2025 21:30:00 CEST | Press release
Nokia Corporation: Repurchase of own shares on 02.04.2025
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom